Study summary

Luspatercept freed more people from transfusions than the standard red-cell booster

COMMANDS trial · 363 people, phase 3 · Published July 2024, Lancet Haematology; FDA approved for first-line use 2023

What was tested

Luspatercept, an injection that helps red blood cells mature, against epoetin alfa (the long-standing standard), as the first anemia treatment for lower-risk MDS in people needing regular transfusions.

What they found

• 60% of people on luspatercept went at least 12 weeks without transfusions and with a meaningful hemoglobin rise, vs 35% on epoetin alfa.
• High blood pressure was the most common serious side effect (10%).

What it means

Moved luspatercept ahead of epoetin as the first treatment for anemia in many people with lower-risk MDS.